All News Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
2.26 ^USD	-4.24%		-15.36%	+52.70%

02/05	Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
02/05	Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cardiff Oncology to Present at the Jefferies Healthcare Conference	30/05	AQ
Cardiff Oncology to Present at Upcoming Investor Conferences in May	14/05	AQ
Cardiff Oncology: Q1 Earnings Snapshot	03/05	AQ
Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update	03/05	AQ
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update	26/04	AQ
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study	09/04	AQ
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	09/04	CI
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?	26/03	PR
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024	07/03	AQ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	06/03	MT
Sector Update: Health Care Stocks Rising Late Afternoon	02/03	MT
Sector Update: Health Care	02/03	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	02/03	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	01/03	MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	01/03
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	01/03	AQ
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	01/03	CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	01/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

All News

Filters